Calamos Advisors
CHRS icon

Calamos Advisors’s Coherus Oncology CHRS Stock Holding History

Calamos Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-185,328
Closed -$3.75M – 778
2019
Q3 		$3.75M Buy
185,328
+141,364
+322% +$2.82M 0.02% 557
2019
Q2 		$972K Buy
+43,964
New +$764K 0.01% 648

Other funds holding CHRS

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Calamos Advisors's CHRS Position: Q4 2019 in Review

Calamos Advisors sold out of Coherus Oncology (CHRS) in Q4 2019, closing a stake of 185,328 shares — an estimated $3.75M sold.

Calamos Advisors first reported a position in CHRS in Q2 2019 and held it in 2 quarters. The position peaked at $3.75M in Q3 2019. 188 funds tracked by Wall St. Rank hold CHRS as of Q4 2019.

  • Calamos Advisors reported no remaining Coherus Oncology position as of Q4 2019 after selling out during the quarter.
  • Calamos Advisors sold 185,328 Coherus Oncology shares in Q4 2019, an estimated $3.75M.
  • Calamos Advisors first reported a position in Coherus Oncology in Q2 2019 and held it in 2 quarters.
  • Calamos Advisors's Coherus Oncology position peaked at $3.75M in Q3 2019.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2019.

Based on Calamos Advisors's 13F filing for Q4 2019, filed 15 Jan 2020.